Company Analysis: Cardio Diagnostics Holdings Inc. (CDIO)

Introduction

Cardio Diagnostics Holdings Inc. is a biotechnology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular disease. Founded in 2017 and headquartered in Chicago, Illinois, the company aims to improve the prevention, detection, and management of cardiovascular diseases through advanced technologies.

Corporate Structure

• Employee Count: Cardio Diagnostics Holdings Inc. employs between 11 to 50 individuals.
• Key Personnel: The company is led by Dr. Meesha Dogan, who serves as CEO. Other notable personnel include Wendy Betts (Information Security Officer) and Damon Broyles (VP, Clinical Innovation). The recent appointment of Dr. Vimal Ramjee as a Strategic Advisor enhances the company's clinical expertise.

Recent Developments and News

• Reverse Stock Split Announcement: On May 8, 2025, Cardio Diagnostics announced a 1-for-30 reverse stock split effective May 13, 2025. This action aims to comply with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The number of outstanding shares will decrease from approximately 52 million to about 1.7 million.

  • .

• Product Offerings: The company offers several clinical tests, including:

  • Epi+Gen CHD: A three-year risk assessment clinical blood test for coronary heart disease.
  • PrecisionCHD: An integrated epigenetic-genetic clinical blood test for coronary heart disease detection.
  • Actionable Clinical Intelligence: A platform providing insights to clinicians for chronic care management.

Financial and Strategic Aspects

• Stock Performance: As of May 8, 2025, the stock price of CDIO is $0.20, reflecting a price change of -50.16%. The trading volume stands at 342,039 shares.
• Revenue and Losses: In 2024, the company reported revenue of $34,890, a 104.45% increase from $17,065 in 2023. Losses amounted to -$8.38 million, which is slightly higher than the previous year.
• Market Position: Cardio Diagnostics operates in the healthcare sector, specifically within the biotechnology industry. The company has developed proprietary technologies that aim to address the growing demand for precision medicine in cardiovascular care.

Market Position and Industry Context

Cardio Diagnostics Holdings Inc. is part of a competitive landscape in the biotechnology sector, focusing on cardiovascular health. The company's approach, utilizing AI and epigenetics, aims to differentiate its offerings in a market that increasingly values personalized healthcare solutions. The recent reverse stock split is part of a strategy to enhance its market standing and comply with regulatory requirements.

TL;DR

Cardio Diagnostics Holdings Inc. (CDIO) announced a 1-for-30 reverse stock split effective May 13, 2025, to meet Nasdaq listing requirements. The company reported revenue of $34,890 in 2024, with losses of -$8.38 million. The stock price is currently $0.20, down 50.16%. Cardio Diagnostics focuses on AI-driven cardiovascular diagnostics, positioning itself within the biotechnology sector.